Clinical trial
Mechanisms of Weight Loss Due to Dual GIP GLP-1 Receptor Agonism With Tirzepatide Compared to Semaglutide: A Randomized Controlled Trial
NCT07900074 is registered in ClinicalTrials.gov with McMaster University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Mechanisms of Weight Loss Due to Dual GIP GLP-1 Receptor Agonism With Tirzepatide Compared to Semaglutide: A Randomized Controlled Trial
- Lead sponsor
- McMaster University
- Phase
- Phase 4
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- December 31, 2029
- Enrollment
- 80 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
obesity (disorder)
Arms
As registered; 2 arms.
-
Semaglutide
This group will take semaglutide once weekly for 12 weeks. Participants will be started at 0.25 mg and increase by one dose level every 4 weeks, if tolerated (allowing up to 3 dose levels over 12 weeks), to a maximum dose of 1 mg. Dose levels are 0.25 mg, 0.5 mg, 1 mg.
-
Tirzepatide
This group will take tirzepatide once weekly for 12 weeks. Participants will be started at 2.5 mg and increase by one dose level every 4 weeks, if tolerated (allowing up to 3 dose levels over 12 weeks), to a maximum dose of 7.5 mg. Dose levels are 2.5 mg, 5 mg, 7.5 mg.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
24-hour Energy Expenditure Measured Using Whole Room Indirect Calorimetry
24-hour energy expenditure will be measured using whole room indirect calorimeter. Metabolic rate in kcal/day will be estimated using the Weir formula, from inspired oxygen and expired carbon dioxide measured every minute by software in the Promethium System, summed over 23 hours and extrapolated to 24 hours by multiplying by 24/23.
Lead sponsor's other trials
McMaster University, most recent start first.
+735 more trials See the organization page
Similar trials
Same condition (Weight Loss) and phase, most recent start first.
+76 more trials See the condition page